On the contrary, reduced IGF-I levels at baseline in specific settings of patients can be explained by the presence of advanced metastatic disease, while the increase in IGF-I levels during therapy may reflect the improvement of metabolic conditions and performance status [41–43]. This evidence concerns the gene IGF1 and metastatic neoplasm.